88IV - PR Newswire Asia's news - Medical/Pharmaceuticals

< Previous page

| Title only | Print

Next page >

Convergen Secures $15 Million Seed+ Financing to Advance Therapeutics for Protein Aggregation Diseases SUZHOU, China , Aug. 31, 2026 /PRNewswire/ -- Convergen, a biotechnology company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, today ... 2026-08-31T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum CS2009 Achieved Key Clinical Validations for Efficacy and Safety ... 2026-08-31T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
T-MAXIMUM B7-H3-Targeted Allogeneic CAR-T Therapy MT027 Receives FDA Fast Track Designation, Accelerating Global Development for Intracranial Solid Tumors MT027 has previously been granted FDA Orphan Drug Designation and has entered Phase II clinical development in recurrent glioblastoma ... 2026-08-31T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Fosun International Holds 2026 Interim Results Presentation: Unlocking Core Pathways, Accelerating Growth in Industries where we Excel HONG KONG , Aug. 31, 2026 /PRNewswire/ -- On the morning of 28 August, Fosun International held its 2026 interim results presentation in Hong Kong. This marks Fosun's return to Hong Kong to ... 2026-08-31T Health Care/Hospital Insurance Medical/Pharmaceuticals
Samsung Biologics publishes prospectus for PolyPeptide public tender offer Direct subsidiary Samsung Peptide AG acting as formal offeror of the public tender offer Publication of offer prospectus follows pre-announcement on July 20, 2026 Largest individual shareholder committed ... 2026-08-31T Biotechnology Chemical Health Care/Hospital Medical/Pharmaceuticals
Subsidised Access to Columvi® Now Available for Eligible Patients with Relapsed or Refractory DLBCL in Singapore Columvi (glofitamab) will be added to the Cancer Drug List (CDL) and Medication Assistance Fund (MAF) on 1 September 2026 for eligible patients with relapsed or refractory diffuse large B-cell lymphoma ... 2026-08-31T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
WuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion SHANGHAI , Aug. 31, 2026 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), ... 2026-08-31T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Data4Life and Monash Health Announce Strategic Collaboration to Advance Clinical Research Data4Life and Monash Health have partnered to optimize clinical trial design and execution, complemented by educational workshops and professional training programs, with a shared commitment to improving ... 2026-08-31T Computer/Electronics Health Care/Hospital Medical Equipment Medical/Pharmaceuticals
Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management - Expected to enroll approximately 4,600 participants with obesity or overweight across two pivotal trials (AURORA-1 and AURORA-2) in the U.S., Europe, and Canada. ... 2026-08-30T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Tycoon Group Sustains Profitability: 2026 Interim Results Net Profit Surges 183% Year-on-Year Business Demonstrates Strong Resilience, ... 2026-08-29T Health Care/Hospital Medical/Pharmaceuticals Retail

< Previous page

Next page >

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2026

Suntek Computer Systems Limited.

All rights reserved